



# MATERIAL SAFETY DATA SHEET

Revision date: 02-Jan-2007

Version: 1.1

Page 1 of 7

## 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

**Pfizer Inc**  
Pfizer Pharmaceuticals Group  
235 East 42nd Street  
New York, New York 10017  
1-212-573-2222

**Pfizer Ltd**  
Ramsgate Road  
Sandwich, Kent  
CT13 9NJ  
United Kingdom  
+00 44 (0)1304 616161

Emergency telephone number:  
CHEMTREC (24 hours): 1-800-424-9300

Emergency telephone number:  
ChemSafe (24 hours): +44 (0)208 762 8322

### Material Name: Claramid (Roxithromycin) Tablets

**Trade Name:** CLARAMID Tablets, 150 mg  
**Chemical Family:** Mixture  
**Intended Use:** Pharmaceutical product used as Antibacterial

## 2. COMPOSITION/INFORMATION ON INGREDIENTS

### Hazardous

Ingredient	CAS Number	EU EINECS List	%
Roxithromycin	80214-83-1	Not listed	150 mg***
Talc (non-asbestiform)	14807-96-6	238-877-9	*
Titanium dioxide	13463-67-7	236-675-5	*
Corn Starch	9005-25-8	232-679-6	*
Magnesium stearate	557-04-0	209-150-3	*
Propylene glycol	57-55-6	200-338-0	*
Silicon dioxide, colloidal NF	7631-86-9	231-545-4	*

Ingredient	CAS Number	EU EINECS List	%
Hydroxypropyl cellulose	9004-64-2	Not listed	*
Hypromellose	9004-65-3	Not listed	*
Povidone	9003-39-8	Not listed	*
Glucose	50-99-7	200-075-1	*
Poloxalene	9003-11-6	Not listed	*

### Additional Information:

\* Proprietary  
\*\*\* per tablet/capsule/lozenge/suppository

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

## 3. HAZARDS IDENTIFICATION

**Appearance:** White tablet

**Statement of Hazard:** May cause allergic skin and respiratory reaction

### Additional Hazard Information:

**Short Term:** Accidental ingestion may cause effects similar to those seen in clinical use.  
**Long Term:** Repeated inhalation may result in sensitization.

## MATERIAL SAFETY DATA SHEET

Material Name: Claramid (Roxithromycin) Tablets  
Revision date: 02-Jan-2007

Page 2 of 7  
Version: 1.1

**Known Clinical Effects:** May cause effects similar to those generally seen in clinical use of antibiotics including gastrointestinal irritation, vomiting, transient diarrhea, nausea, and abdominal pain. Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions. Serious allergic reactions, including anaphylaxis, have been reported. Occasional, transient changes reported in liver function tests, but no liver damage seen.

**EU Indication of danger:** Harmful

**EU Hazard Symbols:**



**EU Risk Phrases:** R42/43 - May cause sensitization by inhalation and skin contact.

**Note:** This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

### 4. FIRST AID MEASURES

**Eye Contact:** Rinse thoroughly with plenty of water, also under the eyelids. If irritation occurs or persists, get medical attention.

**Skin Contact:** Wash skin with soap and water. If irritation occurs or persists, get medical attention.

**Ingestion:** Get medical attention. Do not induce vomiting unless directed by medical personnel. Never give anything by mouth to an unconscious person.

**Inhalation:** Remove to fresh air. If discomfort persists, get medical attention.

### 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Water, carbon dioxide, dry chemical or foam

**Hazardous Combustion Products:** Emits toxic fumes of carbon monoxide, carbon dioxide, and nitrogen oxides.

**Fire Fighting Procedures:** During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

**Fire / Explosion Hazards:** Not applicable

### 6. ACCIDENTAL RELEASE MEASURES

**Health and Safety Precautions:** Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

**Measures for Cleaning / Collecting:** Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

**Measures for Environmental Protections:** Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

## MATERIAL SAFETY DATA SHEET

Material Name: Claramid (Roxithromycin) Tablets  
Revision date: 02-Jan-2007

Page 3 of 7  
Version: 1.1

**Additional Consideration for Large Spills:** Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

### 7. HANDLING AND STORAGE

**General Handling:** If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes.

**Storage Conditions:** Keep container tightly closed when not in use. Store out of direct sunlight in a well ventilated area at room temperature.

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

#### Talc (non-asbestiform)

OSHA - Final PELs - Table Z-3 Mineral D: = 20 mppcf TWA  
ACGIH Threshold Limit Value (TWA) = 2 mg/m<sup>3</sup> TWA  
Australia TWA = 2.5 mg/m<sup>3</sup> TWA containing no asbestos fibers

#### Titanium dioxide

OSHA - Final PELs - TWAs: = 15 mg/m<sup>3</sup> TWA total  
ACGIH Threshold Limit Value (TWA) = 10 mg/m<sup>3</sup> TWA  
Australia TWA = 10 mg/m<sup>3</sup> TWA

#### Corn Starch

OSHA - Final PELs - TWAs: = 15 mg/m<sup>3</sup> TWA total  
= 5 mg/m<sup>3</sup> TWA  
ACGIH Threshold Limit Value (TWA) = 10 mg/m<sup>3</sup> TWA  
Australia TWA = 10 mg/m<sup>3</sup> TWA

#### Magnesium stearate

ACGIH Threshold Limit Value (TWA) = 10 mg/m<sup>3</sup> TWA except stearates of toxic metals  
Australia TWA = 10 mg/m<sup>3</sup> TWA

#### Propylene glycol

Australia TWA = 10 mg/m<sup>3</sup> TWA  
= 150 ppm TWA  
= 474 mg/m<sup>3</sup> TWA

#### Silicon dioxide, colloidal NF

OSHA - Final PELs - Table Z-3 Mineral D: (80)/(% SiO<sub>2</sub>) mg/m<sup>3</sup> TWA  
= 20 mppcf TWA  
Australia TWA = 2 mg/m<sup>3</sup> TWA

The exposure limit(s) listed for solid components are only relevant if dust may be generated.

**Engineering Controls:** Engineering controls should be used as the primary means to control exposures.

#### Personal Protective Equipment:

**Hands:** Not required for the normal use of this product. Wear protective gloves when working with large quantities.  
**Eyes:** Not required under normal conditions of use. Wear safety glasses or goggles if eye contact is possible.  
**Skin:** Not required for the normal use of this product. Wear protective clothing when working with large quantities.  
**Respiratory protection:** Not required for the normal use of this product. If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

# MATERIAL SAFETY DATA SHEET

Material Name: Claramid (Roxithromycin) Tablets  
Revision date: 02-Jan-2007

Page 4 of 7  
Version: 1.1

## 9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State:	Tablet	Color:	White
Molecular Formula:	Mixture	Molecular Weight:	Mixture

## 10. STABILITY AND REACTIVITY

Stability:	Stable
Conditions to Avoid:	None known
Incompatible Materials:	As a precautionary measure, keep away from strong oxidizers.

## 11. TOXICOLOGICAL INFORMATION

**General Information:** The information included in this section describes the potential hazards of the individual ingredients.

### Acute Toxicity: (Species, Route, End Point, Dose)

#### Talc (non-asbestiform)

Rat Oral LD50 > 1600 mg/kg

#### Titanium dioxide

Rat Oral LD50 > 7500 mg/kg

Rat Subcutaneous LD 50 50 mg/kg

#### Magnesium stearate

Rat Oral LD50 > 2000 mg/kg

Rat Inhalation LC50 > 2000 mg/m<sup>3</sup>

#### Povidone

Rat Oral LD50 100 g/kg

#### Glucose

Rat Oral LD50 25800 mg/kg

#### Roxithromycin

Rat Oral LD 50 830 mg/kg

Mouse Oral LD 50 665 mg/kg

#### Hypromellose

Rat Oral LD50 > 10,000 mg/kg

#### Propylene glycol

Mouse Oral LD50 22,000 mg/kg

Rat Oral LD50 20,000 mg/kg

Rabbit Dermal LD50 20,800 mg/kg

**Acute Toxicity Comments:** A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

### Irritation / Sensitization: (Study Type, Species, Severity)

## MATERIAL SAFETY DATA SHEET

Material Name: Claramid (Roxithromycin) Tablets  
Revision date: 02-Jan-2007

Page 5 of 7  
Version: 1.1

### Propylene glycol

Skin Irritation Rabbit Mild

Eye Irritation Rabbit Mild

### Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

#### Roxithromycin

Bacterial Mutagenicity (Ames) *Salmonella* Negative

**Carcinogen Status:** See below

#### Talc (non-asbestiform)

**IARC:** Group 3

#### Titanium dioxide

**IARC:** Group 2B

**OSHA:** Present

#### Povidone

**IARC:** Group 3

#### Silicon dioxide, colloidal NF

**IARC:** Group 3

## 12. ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been investigated. Releases to the environment should be avoided.

## 13. DISPOSAL CONSIDERATIONS

**Disposal Procedures:** Dispose of waste in accordance with all applicable laws and regulations.

## 14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

## 15. REGULATORY INFORMATION

**EU Symbol:** Xn

**EU Indication of danger:** Harmful

**EU Risk Phrases:**

# MATERIAL SAFETY DATA SHEET

Material Name: Claramid (Roxithromycin) Tablets  
Revision date: 02-Jan-2007

Page 6 of 7  
Version: 1.1

R42/43 - May cause sensitization by inhalation and skin contact.

## EU Safety Phrases:

S22 - Do not breathe dust.  
S24 - Avoid contact with skin.  
S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection.

## OSHA Label:

May cause allergic skin and respiratory reaction

## Canada - WHMIS: Classifications

### WHMIS hazard class:

Class D, Division 2, Subdivision A



### Roxithromycin

Standard for the Uniform Scheduling  
for Drugs and Poisons: Schedule 4

### Hydroxypropyl cellulose

Inventory - United States TSCA - Sect. 8(b) XU  
Australia (AICS): Present

### Hypromellose

Inventory - United States TSCA - Sect. 8(b) XU  
Australia (AICS): Present  
Standard for the Uniform Scheduling  
for Drugs and Poisons: Schedule 4

### Talc (non-asbestiform)

Inventory - United States TSCA - Sect. 8(b) Present  
Australia (AICS): Present  
EU EINECS List 238-877-9

### Titanium dioxide

Inventory - United States TSCA - Sect. 8(b) Present  
Australia (AICS): Present  
EU EINECS List 236-675-5

### Corn Starch

Inventory - United States TSCA - Sect. 8(b) XU  
Australia (AICS): Present  
EU EINECS List 232-679-6

### Povidone

Inventory - United States TSCA - Sect. 8(b) XU  
Australia (AICS): Present

### Glucose

# MATERIAL SAFETY DATA SHEET

Material Name: Claramid (Roxithromycin) Tablets  
Revision date: 02-Jan-2007

Page 7 of 7  
Version: 1.1

---

<b>Inventory - United States TSCA - Sect. 8(b)</b>	Present
<b>Australia (AICS):</b>	Present
<b>EU EINECS List</b>	200-075-1
<b>Magnesium stearate</b>	
<b>Inventory - United States TSCA - Sect. 8(b)</b>	Present
<b>Australia (AICS):</b>	Present
<b>EU EINECS List</b>	209-150-3
<b>Propylene glycol</b>	
<b>Inventory - United States TSCA - Sect. 8(b)</b>	Present
<b>Australia (AICS):</b>	Present
<b>EU EINECS List</b>	200-338-0
<b>Silicon dioxide, colloidal NF</b>	
<b>Inventory - United States TSCA - Sect. 8(b)</b>	Present
<b>Australia (AICS):</b>	Present
<b>EU EINECS List</b>	231-545-4
<b>Poloxalene</b>	
<b>Inventory - United States TSCA - Sect. 8(b)</b>	XU
<b>Australia (AICS):</b>	Present

## 16. OTHER INFORMATION

**Reasons for Revision:** Updated Section 2 - Composition / Information on Ingredients. Updated Section 3 - Hazard Identification. Updated Section 5 - Fire Fighting Measures. Updated Section 6 - Accidental Release Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 11 - Toxicology Information. Updated Section 13 - Disposal Considerations.

**Prepared by:** Toxicology and Hazard Communication  
Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied.

**End of Safety Data Sheet**